ITGR

Business Context and Reporting Period

Company: Greatbatch, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 1, 2011 (13-week quarter)
Business Overview: Greatbatch operates two reportable segments: Greatbatch Medical (designing/manufacturing medical devices for cardiac rhythm management, neuromodulation, vascular access, and orthopaedics) and Electrochem Solutions (electrochemical cells and wireless sensors for industrial applications).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 13% year-over-year to a record $148.8 million. Growth was driven by double-digit increases in Vascular Access (+28%), Orthopaedic (+34%), and Electrochem (+19%) segments. CRM/Neuromodulation sales grew slightly by 1%.
• Profitability: Net income surged 115% to $11.9 million. This was significantly aided by a one-time pre-tax gain of $4.5 million from the sale of a cost method investment (IntElect Medical, Inc.).
• Adjusted Metrics: Management reported Adjusted Operating Income of $18.7 million (12.6% margin), up from $15.0 million (11.4% margin) in Q1 2010. Adjusted Diluted EPS was $0.46, compared to $0.32 in the prior year.
• Cash Flow: Net cash provided by operating activities increased 18% to $25.0 million. Net cash provided by investing activities turned positive ($4.2 million) due to proceeds from the investment sale, offsetting capital expenditures.
• Expense Management: Other operating expenses decreased 83% to $0.2 million, primarily due to the absence of facility shutdown and integration costs recorded in the prior year.

Guidance, Outlook, and Risks

• 2011 Sales Guidance: Management reaffirmed full-year 2011 sales guidance of $540 million to $560 million, noting results are trending toward the higher end of the range.
• CRM Outlook: Full-year 2011 CRM and neuromodulation revenue is expected to be consistent with 2010 levels, facing continued pricing pressures and market slowdowns.
• Capital Expenditures: Expected capital spending for the remainder of 2011 is $25 million to $35 million, including a $17 million investment in a new 80,000 sq. ft. manufacturing facility in Allen County, IN.
• Strategic Initiatives: The company is executing a strategy to deliver complete medical devices (via the QiG Group), with the first revenues from this strategy recognized in Q1 2011.
• Risks and Contingencies:
  • Customer Concentration: Four customers (Boston Scientific, Johnson & Johnson, Medtronic, St. Jude Medical) accounted for 60% of sales in Q1 2011.
  • Regulatory: Potential negative impacts from the Patient Protection and Affordable Care Act (Health Care Reform) and proposed regulations on the transportation of lithium batteries.
  • Foreign Currency: Significant exposure to Euro, Mexican Peso, and Swiss Franc fluctuations; a 10% change in USD value could impact annual sales by approximately $11 million.

Key Facts for Investor Verification

• One-Time Gain Impact: Verify the sustainability of earnings by excluding the $4.5 million pre-tax gain from the sale of the IntElect investment, which significantly inflated GAAP net income and EPS.
• Customer Concentration: Assess the risk associated with 60% of revenue coming from four major OEM customers and the potential for pricing pressure from these entities.
• Debt Covenants: Confirm continued compliance with credit facility covenants (Adjusted EBITDA/Interest Expense ratio of 3.00:1 and Leverage ratio of 4.50:1), though the company reported strong compliance (15.1:1 and 1.96:1 respectively) as of April 1, 2011.
• Capital Allocation: Monitor the execution of the $17 million new facility construction and the broader $25-$35 million capital expenditure plan for the year.
• Adjusted vs. GAAP: Review the reconciliation of GAAP to Adjusted metrics, specifically the treatment of non-cash convertible note discount amortization ($2.1 million) and R&D design verification testing costs.